EICHOR

Recruiting studies: Tcr T Cells

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Che
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06383572 Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT07570563 TCR-T Cell Therapy on Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05438667 A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
Phase 1 · 7 location(s) · SCG Cell Therapy Pte. Ltd. · NCT06617000 TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
Phase 2 · 1 location(s) · Johns Hopkins All Children's Hospital · NCT04356469 Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients W
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06904066 An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Guangzhou FineImmune Biotechnology Co., LTD. · NCT06942143 Clinical Study of EBV-TCR-T Cells for EBV-associated Hemophagocytic Lymphohistiocytosis or EBV Infection
Phase 1 · 1 location(s) · Chinese PLA General Hospital · NCT06135922 TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic D
Phase 2 · 1 location(s) · Johns Hopkins All Children's Hospital · NCT04414046 A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transpl
Phase 3 · 26 location(s) · TScan Therapeutics, Inc. · NCT07702578 A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R
Phase 1/Phase 2 · 31 location(s) · AstraZeneca · NCT06542250 ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Phase 1/Phase 2 · 21 location(s) · Immatics US, Inc. · NCT03686124 MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
Phase 1/Phase 2 · 1 location(s) · Erasmus Medical Center · NCT04729543 KSH01-TCRT Solid Tumors
EARLY_Phase 1 · 1 location(s) · TCRx Therapeutics Co.Ltd · NCT05539833 An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Repertoire Immune Medicines · NCT07293754 Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT05296564 Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Phase 1/Phase 2 · 1 location(s) · Daihong Liu · NCT07368634 A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03412877 NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Phase 1 · 2 location(s) · Centre Hospitalier Universitaire Vaudois · NCT06889766 T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid
Phase 1 · 2 location(s) · Tao Zhang · NCT06484556 Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
Phase 1/Phase 2 · 2 location(s) · Chinese PLA General Hospital · NCT06321289 T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid
Phase 1 · 1 location(s) · TingBo Liang · NCT06478251 E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
Phase 1/Phase 2 · 2 location(s) · Christian Hinrichs · NCT05639972 Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
Phase N/A · 1 location(s) · University of Southern California · NCT03921047 Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
Phase N/A · 3 location(s) · Copenhagen University Hospital at Herlev · NCT06234306 HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
Phase 1 · 1 location(s) · Shanghai Ruiliyuan Biotechnology Co., Ltd. · NCT06515314 Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
NA · 1 location(s) · Alice Bertaina · NCT04249830 T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid
Phase 1 · 1 location(s) · Ting Deng · NCT06484790 FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Fred Hutchinson Cancer Center · NCT07645469

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →